Design: Prospective study on 987 thyroid nodules consecutively referred for FNA. US images were independently reviewed by four experts for assignment of malignancy risk. Cytologically benign nodules had confirmation with a second FNA, whereas Bethesda class IV, V, and VI nodules were operated upon. Class III nodules had surgery or follow-up on the basis of clinical, immunocytochemical, and US features.
predictive for malignancy (3, 4, 6, 7) . Similarly, the absence of suspicious sonographic signs may not be considered conclusively diagnostic for a benign lesion (8) . In addition, descriptive US reports frequently do not clearly define the risk of malignancy of nodules under evaluation and may result in an inappropriate use of invasive diagnostic procedures (9) . In 2009, the Thyroid Imaging Reporting and Data System (TIRADS) was proposed for a stratification of the estimated risk of cancer and the indication to thyroid FNA (10) . This US classification scheme was based on the hypothesis that the risk of thyroid malignancy increases in parallel with the increasing number of suspicious US features and with the absence of benign signs. During the following years, major endocrine societies have proposed further classification systems of thyroid US findings. Specifically, the British Thyroid Association (BTA) thyroid cancer guidelines (GLs) (11) in 2014, the American Thyroid Association (ATA) GLs (3) in 2015, and the American Association of Clinical Endocrinologists (AACE/ACE/AME) GLs in 2016 published different modalities of US classifications to be used for a grading of the risk of malignancy of thyroid lesions (4) .
Aims of our study were: (1) to compare, prospectively, in a consecutive series of thyroid nodules referred for FNA, cancer prevalence in the different classes of these US classification systems; (2) to assess their sensitivity, specificity, and diagnostic accuracy for malignancy; and (3) to define their interobserver agreement.
Subjects and Methods
This prospective observational study received Bio-Ethics Committee review and approval and followed the tenants of the Declaration of Helsinki. The design of the study is summarized in Fig. 1 . One thousand one hundred thyroid nodules from 789 white patients (181 male and 608 female, mean age: 55 6 14 years) were referred for US-guided FNA at the Regina Apostolorum Thyroid Center from seven endocrine clinics operating in the greater Rome area, with about three million citizens. Patients were consecutively (January to September 2016) evaluated with B-mode US, color Doppler, and elastographic examination. All sonographic examinations were performed with two identical state-of-the-art US machines (Esaote Twin, Genoa, Italy) equipped with a 5-to 15-MHz linear transducer and with color Doppler, power Doppler, and elastography software.
Patients with class I of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) or an incomplete assessment were excluded from the study (Fig. 1) . Specifically, the assessment was considered incomplete in 39 patients who, after the first cytological evaluation (26 class II and 9 class III cytology cases), did not repeat a second FNA or who (4 class IV cases) did Figure 1 . Flowchart of the study. *Note: 75 class III nodules were considered as benign and followed up after a class II cytology result at second FNA, and 46 class III nodules with confirmation at second FNA of a class III cytology were considered as benign in presence of favorable clinical, US, and immunocytochemical findings.
not undergo surgery and were lost at follow-up. Nine hundred eighty-seven nodules had complete data and were considered in the present series. During the real-time sonographic examination that preceded FNA, thyroid US images were independently evaluated by four examiners for the assignment of the malignancy risk according to the ATA, BTA, and AACE/ACE/ AME GLs on the basis of the US features described in their classification systems (Table 1 ). In case of uncertainty (31 cases in the ATA, 21 cases in the BTA, and 8 cases in the AACE/ACE/ AME classification), a conclusive rating was obtained by a consensus of the majority of the examiners. The operators (R.G., F.G., A.B., and G.B.) had specific experience in endocrine neck US examination for a time that ranged from 9 to 21 years. Each of them performed about 1000 thyroid US examinations Elastographic findings were rated according to a previously reported four-class system with an increasing stiffness from I to IV (13) . FNA was performed under US guidance according to the previously described procedure (3, 4) , and cytological samples were classified in six diagnostic categories according to the TBSRTC (14) . To decrease the risk of false-negative results, patients enrolled in the current study had a second FNA 6 to 8 months after the first cytological assessment (15) . Cystic or predominantly cystic lesions (liquid component .80%) with no suspicious clinical or US signs were considered as benign after two FNA samples characterized by colloid or hemorrhagic fluid and the absence of thyroid cells with atypia (16) . Class III cytology nodules had a second FNA for cytological assessment and determination of a panel of immunocytochemical markers (HBME-1, Galectin-3, CK-19) (17, 18) . Class III patients who, at repeat FNA, showed a class II cytology in absence of suspicious signs had strict follow-up. The confirmed class III cytology nodules with positive immunocytochemistry or any suspicious finding were submitted to surgery, whereas those with favorable immunocytochemical and clinical features were followed up. Class IV, V, and VI of TBSRTC nodules were committed to surgical treatment ( Fig. 1 ). The cytological and histological outcomes were blindly compared with the assigned US classes. To compare the global sensitivity, specificity, accuracy, and negative and positive predictive value for malignancy of different classifications systems, three major US categories were generated pooling together the classes characterized by a similar estimated risk of cancer ( Table 1 ). The comparison of the high-risk US classes vs low-and intermediate-risk categories (Table 2A) and of the high-and intermediate-risk vs the low-risk categories (Table 2B) The interobserver agreement was retrospectively assessed on 250 (25.3%) of the 987 thyroid lesions. US images were randomly selected and blindly examined and scored by the four previously mentioned imaging experts.
Statistical analysis
Clinical, US, cytologic, and pathological findings were separately registered and blind processed for statistical evaluation. Statistical analysis was performed using the Statistical Package for Social Science release 15.0 (SPSS statistical model 15.0; IBM). All data were first analyzed for normality of distribution using the Kolmogorov-Smirnov test of normality. Continuous variables were expressed as mean 6 standard deviation, categorical variables were displayed as frequencies, and the appropriate parametric or nonparametric test was used to assess significance of the differences between subgroups. On the basis of frequency distribution of different risk malignancy outcome, according to BTA, ATA, and AACE/ACE/AME US classification systems, the sensitivity, specificity, diagnostic accuracy, and positive and negative predictive values were calculated and compared. A P value of less than 0.05 was considered statistically significant.
The interobserver agreement was calculated using cross tabulation expressed in Cohen's k on the basis of the concordance in the classification of 250 thyroid nodules blindly performed by four experienced imaging experts. All k values were interpreted, according to the standards proposed by Landis and Koch (19) 
Results
A series of 1100 thyroid nodules was consecutively evaluated on the basis of the previously reported criteria. Seventy-four nodules (6.7%) with an inadequate cytological report (class I) and 39 (3.5%) patients with incomplete data were excluded from the study. Consequently, our study was based on a series of 987 nodules belonging to 714 consecutive patients. Sonographic features "difficult" to be classified according to the GL criteria were observed in 31 cases (3.1% of the whole series) in the ATA, in 21 cases (2.1%) in the BTA, and in 8 cases (0.8%) in the AACE/ACE/AME classifications. Specifically, category assignment was doubtful in the following circumstances: ATA classification: isoechoic nodules with either irregular margins or microcalcifications, or partially cystic nodules with uncertain eccentric location of the solid area; BTA classification: isoechoic nodules with either central vascularity or microcalcifications, or lesions with intranodular macrocalcifications; and AACE/ACE/AME classification: hyperechoic nodules without suspicious findings. The prevalence of malignancy in nodules difficult to be classified was 19.3% in the ATA, 23.0% in the BTA, and 12.5% in the AACE/ACE/AME, respectively. Out of 987 thyroid lesions (mean maximum diameter: 21.2 6 13.4 mm, range: 6 to 75 mm), 831 (84.2%) nodules were confirmed as benign by the second FNA or by surgery, and 156 lesions (15.8%) were histologically proven to be malignant. Tumor histotypes were as follows: papillary, classic variant: 72 (46.1% of total malignancies); papillary, follicular variant: 47 (30.1%); papillary with diffuse sclerosis: 14 (8.9%); follicular: 15 (9.6%); medullary: 5 (3.2%); anaplastic: 1 (0.6%); and noninvasive follicular thyroid neoplasm with papillary-like nuclear: 2 (1.2%). Importantly, two of the papillary carcinomas (1.5%) showed predominantly cystic features.
Prevalence of malignancy in the different US categories

BTA US classification
Histological malignancy rate was 2.8% in benign; 10.0% in indeterminate; 51.3% in suspicious; and 80.9% in malignant US class, respectively.
ATA US classification
Malignancy rate was 0.0% in benign; 2.2% in very lowsuspicion; 3.0% in low-suspicion; 5.8% in intermediatesuspicion; and 55.0% in high-suspicion US class, respectively.
AACE/ACE/AME US classification
Malignancy rate was 1.1% in low-risk; 4.4% in intermediate-risk; and 54.9% in high-risk US class, respectively.
The prevalence of malignancy in the different classification systems is summarized in Tables 3, 4 , and 5 and in Fig. 2 . Tables 3-5 also report the estimated risk of malignancy of each US classification system as provided by the respective scientific societies (3, 4) . Sensitivity, specificity, and diagnostic accuracy for malignancy
The distribution of the US diagnosis of the high-risk and of the pooled low-and intermediate-risk classes are reported in Tables 3-5 together with their histological or cytological diagnosis. The derived sensitivity, specificity, diagnostic accuracy, negative and positive predictive value, and the OR of each US classification are reported in Table 2 .
The three US classification systems showed similar predictive value for malignancy in their high-risk classes with a slightly better specificity of the BTA (62%) compared with ATA (54%) and AACE/ACE/AME (54%) (P = 0.151 and P = 0.157, respectively). The ATA and AACE/ACE/AME classifications, however, demonstrated a better sensitivity for malignancy (81% and 82%, P = 0.107 and P = 0.108, respectively) than the BTA system (74%).
Interobserver agreement
The interobserver agreement, assessed on the randomly selected sample of 250 cases, resulted in a k correlation coefficient of 78.9%, 76.9%, and 82.0% for the BTA, ATA, and AACE/ACE/AME classification systems, respectively.
Indication to FNA on the basis of US risk classes and dimensional criteria
The distribution of nodules for which the combined use of the US classifications and of their dimensional cutoff indicated FNA is summarized in Table 6 . The estimated risk proposed by the scientific society is also reported. (25/528). In the high-risk class, cytological assessment was recommended in 129 nodules with a malignancy rate of 52.3% (68/129).
Conversely, in the benign and very low-risk classes, according to the ATA criteria, FNA was not recommended in 110 nodules, which showed a 0.0% malignancy rate (0/110). In the low-and intermediate-risk classes, FNA was not recommended in 118 nodules, which carried a malignancy rate of 3.3% (4/118). Therefore, in benign and very low-, low-, and intermediaterisk ATA categories, cytological assessment in the 228 nodules without indication to FNA would have detected, if performed against GL recommendations, four malignant lesions (1.7%) at the cost of a 30% increase of the total number of FNA. In the US high-risk class, FNA was not recommended, according to the dimensional cutoff (,10 mm), in 102 nodules, which carried a malignancy rate of 57.8% (59/102). The histotypes of these tumors were as follows: papillary, classic variant: 42 (68.8%); papillary, follicular variant: 16 (26.2%); follicular: 1 (1.6%); medullary: 1 (1.6%); and noninvasive follicular thyroid neoplasm with papillary-like nuclear: 1 (1.6%).
Interestingly, had nodules ,10 mm been excluded from our analysis, the prevalence of malignancy in the different ATA US classes would be nearly unchanged (Supplemental Table 5 ). Specifically, on the 843 nodules with diameter $10 mm (85.4% of the total series), the prevalence of malignancy in the benign and very low-and low-suspicion categories was completely unaffected. In the indeterminate suspicion category, the prevalence of malignancy was 6.0% vs 5.8%, and in the high-risk class, the prevalence was 52.8% vs 55.0%.
AACE/ACE/AME US classification
In the low-risk class, FNA was recommended in 103 nodules, which carried a malignancy rate of 1.9% (2/103), and in the intermediate-risk class in 302 nodules with a malignancy rate of 4.6% (14/302). As a whole, in these two lower-risk AACE/ACE/AME categories, FNA was indicated in 405 nodules, characterized by a 3.9% (16/405 nodules) prevalence of malignancy. In the high-risk US class, FNA was recommended in 235 nodules, which carried a malignancy rate of 54.8% (129/235).
According to the AACE/ACE/AME dimensional recommendations, in the low-risk US class FNA was not recommended in 77 nodules, which showed a 0.0% prevalence of malignancy (0/77). In the intermediate-risk class, FNA was not indicated in 270 nodules, which carried a 4.0% malignancy rate (11/270). As a whole, in the low-and intermediate-risk categories, FNA on the 347 "not-recommended" nodules would have detected, if performed against the GL recommendations, 11 malignant lesions (3.1% of the lesions without indication) at the cost of a 46.1% increase in the total number of FNAs (347/752 procedures).
Similarly to what was observed for the ATA classification, the prevalence of malignancy in the series of 843 nodules including lesions $10 mm was unchanged in the low-risk class (1.1% vs 1.1%). In the intermediate risk The estimated risk proposed by the scientific society is also reported. The estimated risk proposed by the scientific society is also reported.
category the prevalence of malignancy was 4.5% vs 4.4%, and in the high-risk class, the prevalence was 52.7% vs 54.9% (Supplemental Table 5 ).
BTA US classification
No dimensional cutoff was provided by BTA, so that the indication to FNA was based only on the US risk classification (Tables 3-5 ). In the 445 US indeterminate, suspicious, or malignant nodules (categories U3 to U5), FNA led to the identification of 141 malignant lesions (31.7% of the nodules classified in these three categories). FNA was not indicated by the BTA GL for lesions in the benign US category, so FNA was not recommended in the 542 sonographically benign nodules, which 
Discussion
After the TIRADS proposal in 2009 (10), three major endocrine societies have recommended adding to thyroid US reports a rating score for a reliable communication of the expected risk of malignancy and indication to FNA (3, 4, 11) . The BTA, ATA, and AACE/ACE/AME classification systems are based on similar but not completely matching US findings and are different for the composition and number of classes and their estimated risk of thyroid cancer. However, no prospective blinded study evaluated the actual risk of thyroid cancer on the basis of strictly controlled final outcomes. So, the current study was performed in a series of thyroid nodules referred for FNA to assess, in clinical practice, the usefulness of the US classification systems and the reliability of their size cutoff for cytological assessment.
Prevalence of malignancy
The ATA and the AACE/ACE/AME classifications correlated each of their US classes with an estimated risk of malignancy of thyroid nodules. The expected risk of cancer of these classifications were validated by our study, even if both classification systems showed a malignancy rate slightly lower than expected. This finding could be due to a less stringent selection of nodules referred for FNA or to local reasons, due to the elevated prevalence of multinodular goiter in the great Rome area, a borderline zone for iodine deficiency.
The ATA and the AACE/ACE/AME US categories were highly effective for ruling out the need of FNA in thyroid nodules that were defined as at low US risk. Indeed, the prevalence of thyroid cancer in the ATA benign and very low-and low-risk classes and in the AACE/ACE/AME low-risk classes (0.0%, 2.2%, 3.0%, and 1.1%, respectively) was very low.
Importantly, the number of thyroid nodules classified in the AACE/ACE/AME low-risk category was completely similar to the sum of the nodules categorized in the ATA benign and very low-risk classes (180 vs 43 and 137 cases, respectively). Additionally, the risk of malignancy in the AACE/ACE/AME low-risk class was quite similar to the cancer prevalence observed in the combined benign and very low-risk ATA categories (1.1% vs 1.6%, respectively). Finally, when comparing the AACE/ACE/ AME intermediate-risk category vs the pooled ATA low-and indeterminate-risk categories (including 572 and 576 nodules, respectively), the risk of malignancy was, again, 4.4% vs 4.5% (Tables 3-5) .
The frequency of cancer in the BTA benign class (2.8%) was similar to the ATA low-risk category but was definitely higher than that of the AACE/ACE/AME lowrisk category. This finding makes the BTA benign class less reliable in excluding the indication to FNA.
The AACE/ACE/AME high-risk class and the ATA high-suspicion classes provided a reliable indication to cytological assessment due to their elevated malignancy rate (55.0% and 54.9%, respectively). The BTA classification was not linked to an expected frequency of thyroid cancer, but its high-risk category was significantly more specific than the similar classes of the other two classifications (80.9% cancer rate).
On the basis of these results, the lower number of US categories and the less complicated structure of the AACE/ACE/AME US classification may represent an advantage for routine use in clinical practice. Moreover, the modest difference in the prevalence of cancer in the very low-vs low-suspicion ATA class (2.2% vs 3.0%) seems to hamper the clinical usefulness of the distinction between these two ATA US categories.
Notably, the ATA classification did not reliably categorize 3.1% of the cases, in accordance with the 3.4% frequency reported by Yoon et al. (20) . ATA classification was difficult to be appropriately used. This problem was associated with a frequency fairly higher than in the BTA and AACE/ACE/AME classification (2.1% and 0.9%, respectively).
Interobserver agreement
The three classification systems represent a reliable tool for routine use in clinical practice because they demonstrated a substantial interobserver agreement. The AACE/ ACE/AME US classification showed a slightly better reproducibility between different observers than the BTA and ATA systems (82.0% vs 78.9% and 76.9%, respectively), probably due to the lower number of US categories and the less complicated structure of the classification.
Indication to FNA on the basis of the combined use of US risk classes and size cutoffs
The combined use of thyroid US categories with a dimensional cutoff resulted in a risk-effective selection of patients for FNA in the ATA benign and very low-risk categories (0.0% risk of missed malignancy) and the AACE/ACE/AME low-risk category (0.0% risk of missed malignancy).
In the ATA low-and intermediate-risk classes, the recommended 15-and 10-mm size cutoffs, respectively, for FNA were associated with a low risk (3.3%) of missing malignancies in nodules without indication to FNA. A rather similar result was provided by the 20-mm cutoff proposed by the AACE/ACE/AME classification for its intermediate-risk class (4.0% risk of missed malignancy).
The specificity for malignancy of the high-risk categories was definitely elevated, even if slightly lower than expected in the ATA classification, and represents a strong indication to cytological assessment of all thyroid lesions in this class. Of note, in the 6-to 9-mm high-risk nodules, the malignancy rate was similarly elevated (25.0%) in the ATA and AACE/ACE/AME classifications. The clinical role of these small-sized cancers is still debated, and different recommendations are currently provided about their cytological assessment (3, 4, 11, 21) .
In clinical practice, the use of the ATA US classification with its recommended dimensional cutoff would have saved, in the low-and intermediate-risk classes, 30.1% of FNAs, with a 1.7% rate of missed malignancy in the avoided procedures. In the AACE/ACE/AME intermediate-risk category, the present recommendations would have saved 46.1% of the procedures, with a rate of missed malignancy of 3.1%. In our opinion, in the AACE/ACE/AME intermediate-risk category, the recommendation of a lower cutoff for FNA could be more profitable. For instance, had the size cutoff been fixed at 15 mm instead of 20 mm, the rate of missed cancer would have been lowered to a 2.2% frequency, rather similar to that of the ATA classification.
The BTA classification did not provide a dimensional cutoff for FNA. However, had FNA been avoided in all nodules classified as benign at US examination, FNA would have spared 55% of the procedures, with a 2.8% rate of missed malignancy.
So the use of the US classification systems can substantially decrease the indication to FNA while maintaining the risk of malignancy for thyroid nodules not submitted to cytology at an acceptable low level, nearly approaching the risk of false-negative results reported in benign cytological samples (22) . Moreover, the majority of these potentially missed malignancies would have been characterized by nonaggressive histotypes.
The current study was focused on the validation of thyroid US classification systems proposed until 2016 by three major international endocrine societies and did not consider the initial TIRADS scoring system, due to its complexity in clinical practice, nor the other systems proposed by radiological societies (23) (24) (25) . A retrospective study performed in South Korea demonstrated a prevalence of malignancy in the ATA very low-suspicion category that was more elevated than estimated, thereby questioning its assignment criteria and the recommendation not to perform FNA in this US class (20) . However, our real practice data substantially confirmed the malignancy rate proposed for the low-and very low-risk classes by ATA and AACE/ACE/AME GLs.
Finally, the American College of Radiology has recently released a white paper proposing a TIRADS US classification based on a quantitative scoring system of thyroid nodules (26) . It will be necessary to evaluate the diagnostic accuracy of this new classification system and the usefulness of incorporating its rating scheme into the already validated thyroid nodule US classifications.
The use of ultrasonography scoring systems was reported to provide useful complementary information in thyroid nodules with indeterminate (class III and IV TBSRTC) cytology (27, 28) . Due to the small size of these series and their retrospective design, these data need confirmation in larger prospective dedicated trials.
A limitation of our study is represented by a risk of verification bias concerning the use of clinical and US data as criteria to decide whether the diagnosis would be histologically confirmed in 46 cytological class III nodules.
Conclusions
In our prospective study, performed on a large consecutive series of thyroid nodules referred for FNA, the BTA, ATA, and AACE/ACE/AME US classification systems provided an effective and rather similar malignancy risk stratification. The prevalence of cancer in the various classes was close to the estimated rate of thyroid malignancy, with a frequency of cancer that was slightly lower than preliminarily expected in the high-risk class of the ATA system. In the series of thyroid nodules under evaluation, the use of the imaging reporting systems would have saved from 30% to 46% of the potential FNA procedures, with a low risk of missed malignancy. Due to the lower number of US categories and its less complicated structure, the AACE/ACE/AME US classification seems to be a more practical tool for routine use than the BTA and ATA systems. All of these US classifications, however, appear as reliable scoring systems for clinical practice because of their adequate interobserver agreement.
